This Article Abstract Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Robertson, M. J. Articles by Ritz, J. Search for Related Content PubMed PubMed Citation Articles by Robertson, M. J. Articles by Ritz, J.

Interleukin 12: Basic Biology and Potential Applications in Cancer Treatment

Division of Hematologic Malignancies, Dana-Farber Cancer Institute, and the Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA

Correspondence: Michael J. Robertson, M.D., Division of Hematologic Malignancies, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. Telephone: 617-632-3768; Fax: 617-632-5167; e-mail: michael_robertson{at}dfci.harvard.edu

	ABSTRACT

Top Abstract Introduction Structure of IL-12 and... Production of IL-12 Biologic Activities of IL-12... Antitumor Effects of IL-12... Clinical Trials of IL-12... Conclusion References

 
Interleukin 12 is a heterodimeric cytokine that has potent effects on innate and adaptive immunity. Interleukin 12 induces interferon secretion by T cells and natural killer cells, enhances the proliferation of activated T cells and natural killer cells, augments the cytolytic activity of cytotoxic T lymphocytes and natural killer cells, and supports the differentiation of Th1 helper effector cells. Interleukin 12 stimulates in vitro antitumor activity of lymphocytes from patients with cancer and in vivo antitumor activity in many murine tumor models. Current data indicate that CD4 T cells, CD8 T cells, natural killer cells and interferon may contribute to the antitumor effects of interleukin 12 therapy. However, further investigation is required to elucidate the precise mechanisms involved in the antitumor activity of interleukin 12.

Key Words. Interleukin 12 (IL-12) • Immunotherapy • Biologic therapy • Cytokine therapy • Tumor immunology • Antitumor immunity

	INTRODUCTION

Top Abstract Introduction Structure of IL-12 and... Production of IL-12 Biologic Activities of IL-12... Antitumor Effects of IL-12... Clinical Trials of IL-12... Conclusion References

 
Interleukin 12 (IL-12) is a heterodimeric cytokine that was independently identified by two groups. Trinchieri and colleagues isolated a cytokine called natural killer cell stimulatory factor (NKSF) from the supernatants of B lymphoblastoid cell lines and subsequently cloned cDNA encoding this cytokine in collaboration with investigators at Genetics Institute (Cambridge, MA) [1, 2]. Gately and colleagues at Hoffmann-LaRoche (Nutley, NJ) isolated cDNA encoding a cytokine they had identified and called cytotoxic lymphocyte maturation factor (CLMF) [3, 4]. The deduced amino acid sequences of NKSF and CLMF were found to be identical and the cytokine was thereafter designated IL-12. IL-12 has been shown to exert potent immunostimulatory effects on certain helper T cells, as well as on cytotoxic T lymphocytes (CTL) and natural killer (NK) cells. Preclinical studies suggest that IL-12 may prove useful in the treatment of several human diseases, including atopic and allergic conditions, HIV infection and cancer. This article will focus on the possible role of IL-12 in the treatment of malignant disease. A comprehensive summary of the biology of IL-12 is beyond the scope of this article; topics not dealt with here have been presented in other recent reviews [5–8].

	STRUCTURE OF IL-12 AND THE IL-12 RECEPTOR

Top Abstract Introduction Structure of IL-12 and... Production of IL-12 Biologic Activities of IL-12... Antitumor Effects of IL-12... Clinical Trials of IL-12... Conclusion References

 
Human IL-12 is a disulfide-linked heterodimer with an apparent molecular mass of 70 kDa; it is composed of two subunits with masses of 40 and 35 kDa [1, 3]. The p40 chain is homologous to several cytokine receptors, including the IL-6 receptor and the receptor for ciliary neurotrophic factor [9, 10]. In contrast, p35 is homologous to other cytokines, including IL-6, G-CSF and chicken myelomonocytic growth factor [11]. Neither p40 alone nor p35 alone appears to have significant biologic activity, and a combination of soluble p40 with soluble p35 exhibits bioactivity that is markedly inferior to that of heterodimeric IL-12 [2, 4, 5].

IL-12 receptors (IL-12R) have been demonstrated on resting and activated NK cells, activated CD4 T cells and activated CD8 T cells [12–14]. However, IL-12R have not been detected on resting T cells, resting monocytes, or on resting or activated B cells. Scatchard analysis of radiolabeled IL-12 binding to activated T cells demonstrates three distinct binding sites with high, intermediate and low affinity [15]. Molecular cloning of one component of the IL-12R has been reported [15]. This IL-12R subunit is a member of the hematopoietic cytokine receptor superfamily and is most similar to gp130, a common signaling component of the receptors for IL-6, IL-11, leukemia inhibitory factor and oncostatin M. The available data, however, suggest that the high affinity IL-12R contains one or more additional subunits. Indeed, identification of another putative component of the IL-12R has recently been presented (U. Gubler, presentation at New York Academy of Sciences Conference, November 1995).

Relatively little has been published regarding signal transduction after binding of IL-12 to its cell surface receptor. IL-12 induces rapid tyrosine phosphorylation of mitogen activated protein (MAP) kinase species in activated T cells [16]. However, MAP kinase phosphorylation was not detected in resting T cells or NK cells stimulated with IL-12 [16, 17]. Janus (JAK) kinases and the Stat family of signal transducer and transcription factors have been implicated in signal transduction induced by a variety of hematopoietic cytokines [18, 19]. IL-12 stimulates tyrosine phosphorylation of specific JAK kinases in activated T cells and NK cells [20], and of Stat3 and Stat4 in some CD4 T cell clones [21, 22]. Moreover, IL-12 induces rapid tyrosine phosphorylation of the src family tyrosine kinase lck in resting NK cells [17, 23]. The precise signaling sequence generated by IL-12 stimulation of T cells or NK cells remains to be elucidated.

	PRODUCTION OF IL-12

Top Abstract Introduction Structure of IL-12 and... Production of IL-12 Biologic Activities of IL-12... Antitumor Effects of IL-12... Clinical Trials of IL-12... Conclusion References

 
Regulation of IL-12 production is rendered complex by the heterodimeric structure of this cytokine. Messenger RNA for the p35 subunit is constitutively expressed by many different cell types, whereas the message for p40 is highly restricted and appears to be expressed only by cells that produce heterodimeric IL-12 [24, 25]. Cells that secrete biologically active p40/p35 heterodimers usually also secrete free p40 chains in approximately 10-fold excess. By contrast, secretion of significant amounts of p35 in the absence of p40 has not been reported. In vitro experiments have shown that p40/p40 homodimers can block binding of p40/p35 heterodimers to the IL-12R and can act as competitive antagonists of IL-12 in various bioassays [26, 27]. However, it is unclear what fraction, if any, of physiologically secreted free p40 chains exists as potentially antagonistic homodimers.

Some Epstein-Barr virus-transformed B cell lines constitutively produce IL-12. Phorbol esters strongly augment IL-12 production by B lymphoblastoid cell lines [24]. Several myeloid leukemia and epidermoid carcinoma cell lines can also produce IL-12 after activation [25, 28]. However, the major physiologic source of IL-12 appears to be antigen-presenting cells, including monocytes and macrophages, B cells and dendritic cells [24, 29]. Neutrophils, mast cells and keratinocytes have also been shown to produce IL-12 under certain experimental conditions, but production of IL-12 by T cells or NK cells has not been convincingly demonstrated [28, 30–32]. In contrast to B lymphoblastoid cell lines, normal hematopoietic cells produce little IL-12 in response to phorbol ester. Rather, secretion of IL-12 by normal cells appears to be most effectively stimulated by certain microorganisms [5, 24]. Endotoxin is a particularly potent inducer of IL-12; the other microbial products that stimulate IL-12 production have not been well characterized. Interferon (IFN-) can enhance and IL-10 can inhibit IL-12 production in response to endotoxin or other stimuli [25, 33].

	BIOLOGIC ACTIVITIES OF IL-12 IN VITRO AND IN VIVO

Top Abstract Introduction Structure of IL-12 and... Production of IL-12 Biologic Activities of IL-12... Antitumor Effects of IL-12... Clinical Trials of IL-12... Conclusion References

 
EFFECTS ON CYTOKINE PRODUCTION AND PROLIFERATION OF LYMPHOCYTES
IL-12 is the most potent known stimulus for IFN- production by normal lymphocytes [1, 34, 35]. IL-12 induces IFN- production by resting and activated T cells and NK cells. Several cytokines, including tumor necrosis factor (TNF-), IL-1, IL-2 and IL-15, can act synergistically with IL-12 to stimulate IFN- secretion [34, 36–39]. Furthermore, ligation of the costimulatory receptors CD28 or CD2 synergizes with IL-12 to induce IFN- production by T lymphocytes [40–42]. IL-12 also stimulates in vivo production of IFN- in healthy [43, 44], experimentally infected [37, 45, 46], and tumor-bearing mice [44, 47]. After infection by some obligate intracellular pathogens, IL-12 secreted by activated monocytes, and IFN- secreted by activated NK cells, may amplify the innate immune response and help to contain the infection during the maturation of antigen-specific T and B cell responses [48]. Moreover, IL-12 and IFN- produced during the innate immune response can support the differentiation of activated CD4 and CD8 T cells into effectors of cell-mediated immunity [49, 50]. Other cytokines, including TNF-, IL-3, GM-CSF, M-CSF and IL-8, are produced by T cells or NK cells after IL-12 activation [40, 51–53]. However, IL-12 appears to stimulate less production of TNF in vitro and in vivo compared to IL-2 [47, 51].

IL-12 does not induce the proliferation of resting T cells but can support the growth of T cells that have been activated by mitogens or specific antigens [54–56]. IL-12 can enhance the proliferation of activated CD4 and CD8 /ß T cells as well as / T cells. Similar to IFN- production, T cell proliferation in response to IL-12 is augmented by signals delivered through the CD2 and CD28 surface antigens [40–42]. The effects of IL-12 on NK cell proliferation are complex. IL-12 induces very little proliferation of resting NK cells and, unlike IL-2, cannot support the growth of human NK cells in vitro [51, 56–58]. Moreover, IL-12 inhibits optimal NK cell proliferation in response to IL-2 [56, 57]. IL-12 can also inhibit IL-2-induced proliferation of / T cells [56]. Nevertheless, IL-12 upregulates IL-2 receptor expression on NK cells [51, 57, 59] and enhances NK cell proliferation in response to suboptimal concentrations of IL-2 [51, 56].

EFFECTS ON CYTOTOXIC LYMPHOCYTES
Cytotoxic lymphocytes are operationally defined by their ability to kill other cells. Two major types of cytotoxic lymphocytes have been identified: CTL and NK cells [60]. CTL usually differentiate from activated CD8 T cells, although CD4 T cells can become killer cells under some circumstances. Target cell lysis by CTL is triggered by interactions between T cell receptor heterodimers on the CTL and antigenic peptides bound to major histocompatibility (MHC) glycoproteins on the target cell. CTL are thus described as antigen-specific and MHC-restricted. In contrast, NK cells do not express T cell receptors and their cytotoxicity is not limited to target cells bearing syngeneic MHC antigens [61, 62]. NK cells can lyse certain malignant and virus-infected target cells in a spontaneous, antibody-independent process known as natural killing and can lyse antibody-coated target cells by a process known as antibody-dependent cellular cytotoxicity (ADCC). The NK cell receptor for ADCC consists of oligomeric complexes of CD16, which binds to the Fc portion of IgG, and family members [63]. Although several candidate NK receptors have been described [64–67], the receptors that trigger natural killing have not been unequivocally defined. NK cells also express several different receptors for class I MHC molecules that can deliver negative signals that inhibit cytolysis [68, 69]. The relative sensitivity of target cells to natural killing therefore appears to reflect their relative expression of ligands that engage triggering and inhibitory NK cell receptors. CTL and NK cells may act in a complementary fashion to destroy cells that have been infected by intracellular pathogens or that have undergone malignant transformation [68, 69].

CTL and NK cells are potently stimulated by IL-12, accounting for its former designation as CLMF and NKSF. IL-12 enhances the generation of CTL specific for viral antigens and alloantigens both in vitro and in vivo [43, 70–72]. IL-12 supports the proliferation and differentiation of activated CD8 T cells into CTL effectors and stimulates the cytolytic activity of fully differentiated CTL. Augmentation of CTL responses by IL-12 thus appears to be due to increases in the number of CTL and in the cytotoxicity of CTL on a per-cell basis. The cytolytic activity of NK cells is also potently augmented in vitro and in vivo by IL-12 [43, 51, 57, 70, 73]. IL-12 enhances the in vitro lysis of NK-sensitive and NK-resistant tumor cells, antibody-coated target cells and virus-infected cells [57, 73, 74]. IL-12 stimulates increased expression of cytolytic effector molecules, such as perforin and serine esterases, that are common to both CTL and NK cells [53, 75, 76]. Moreover, IL-12 induces the upregulation of several adhesion molecules involved in binding of NK cells to their target cells [57, 59]. Optimal concentrations of IL-2 generally augment NK cell cytotoxicity to a greater degree than optimal concentrations of IL-12; however, the concentration of IL-12 required for an optimal effect is approximately 100-fold lower on a molar basis compared to that of IL-2.

EFFECTS ON HELPER T CELLS
Activated CD4 T cells can differentiate into two major types of helper effector cell, T helper type 1 (Th1) or Th2 [77]. Th1 cells secrete predominantly IL-2, IFN- and TNF, and support the differentiation of activated CD8 T cells into CTL and of monocytes into macrophages. Th1 cytokines also stimulate the cytolytic activity of NK cells and cause activated B cells to produce antibodies of isotypes that optimally induce ADCC by NK cells and macrophages. Thus, Th1 cells promote cell-mediated immunity to intracellular pathogens, allografts and malignant tumor cells. In contrast, Th2 cells produce IL-4, IL-5 and IL-10, which inhibit the activation of monocytes and NK cells and can cause CD8 T cells to differentiate into noncytotoxic "suppressor" cells. Thus, Th2 cytokines tend to inhibit cell-mediated immunity while promoting eosinophilia and IgE production, which are characteristic of immune responses to allergens and helminths. IL-12 promotes the differentiation of activated CD4 T cells into Th1 effector cells [78]. IL-12 appears to support Th1 development both by direct effects on activated CD4 T cells and indirectly through the induction of IFN- secretion [79–82]. IL-12 also stimulates Th1 effector cell proliferation and cytokine production. IL-12 may thus enhance cell-mediated immunity by its combined effects on the differentiation and function of activated CD4 T cells, CD8 T cells and NK cells.

EFFECTS ON HEMATOPOIETIC CELLS
IL-12 by itself does not appear to support the growth of immature hematopoietic precursors. Nevertheless, IL-12 can augment in vitro proliferation and/or differentiation of human and murine hematopoietic progenitor cells in response to IL-3, stem cell factor and erythropoietin [83–87]. The synergy of IL-12 with other hematopoietic cytokines appears to be due to direct effects on immature hematopoietic cells. When purified NK cells are added to in vitro cultures of human progenitor cells, however, IL-12 can inhibit formation of myeloid and erythroid colonies [85]. This effect appears be mediated by inhibitory cytokines, including IFN- and TNF-, that are produced by IL-12-activated NK cells.

The effects of IL-12 on hematopoiesis in vivo are complicated. Prolonged administration of IL-12 to healthy mice results in bone marrow hypoplasia and lymphopenia; dose-dependent anemia, thrombocytopenia and granulocytopenia also occurred in some studies [43, 88, 89]. Induction of IFN- appears to contribute to the in vivo inhibition of murine hematopoiesis by IL-12 [90]. Lymphopenia, anemia and decreased platelet counts have also been observed after administration of human IL-12 to primates [91, 92]. In squirrel monkeys, however, IL-12 induces peripheral blood lymphocytosis and bone marrow hyperplasia [92]. In both mice and monkeys, IL-12 causes splenomegaly and extramedullary hematopoiesis in the spleen. The hematologic effects of IL-12 in vivo are generally rapidly reversible [88, 91].

	ANTITUMOR EFFECTS OF IL-12 IN PRECLINICAL STUDIES

Top Abstract Introduction Structure of IL-12 and... Production of IL-12 Biologic Activities of IL-12... Antitumor Effects of IL-12... Clinical Trials of IL-12... Conclusion References

 
EFFECTS OF IL-12 ON IN VITRO ANTITUMOR ACTIVITY OF LYMPHOCYTES FROM PATIENTS WITH CANCER
IL-12 can augment the cytolytic activity of lymphocytes from patients with cancer [93–98]. After overnight incubation in picomolar concentrations of IL-12, peripheral blood lymphocytes of cancer patients can lyse both leukemic and solid tumor cell lines [93, 94]. Moreover, IL-12 enhances the lysis of autologous tumor cells by tumor infiltrating lymphocytes from patients with melanoma and ovarian cancer [96, 97]. IL-12 also potently augments the antitumor activity of NK cells obtained from patients with hematologic malignancies undergoing allogeneic bone marrow transplantation [93] and patients with solid tumors that have received prolonged infusions of low-dose IL-2 [57, 93, 99]. IL-2 and IL-12 act additively or synergistically in many of these in vitro experimental systems.

ANTITUMOR EFFECTS OF IL-12 IN HUMAN/SEVERE COMBINED IMMUNODEFICIENCY (SCID) MOUSE MODELS
Mice with SCID lack mature T cells and B cells, and do not reject human tumors or normal human hematopoietic cells. SCID mice have thus been used for in vivo studies of human hematopoiesis and the immunotherapy of human cancers. The growth of pulmonary metastases from human melanoma cells injected intravenously into SCID mice is inhibited by injection of polyclonal activated human NK cells [100]. The antitumor effect of human NK cells in this model is strongly augmented by the systemic administration of human IL-2 and IL-12 in combination. SCID mice injected with a human tumor cell line, U937, rapidly succumb to a disseminated malignancy resembling acute leukemia. Adoptive transfer of a cytotoxic human T cell line prolongs survival of the mice, and this protective effect is enhanced by IL-12 therapy [101]. The SCID mouse studies demonstrate that human cytotoxic lymphocytes can destroy human tumor cells in vivo and that this antitumor activity can be augmented by IL-12.

ANTITUMOR EFFECTS OF SYSTEMICALLY OR LOCALLY ADMINISTERED IL-12 IN ANIMAL MODELS
IL-12 has been shown to have potent antitumor effects in murine models of melanoma, sarcoma, kidney cancer, lung cancer, colon cancer and ovarian cancer [8, 47, 102–105]. Systemic or peritumoral injection of IL-12 can induce complete regression of established tumors, inhibit the formation of distant metastases and substantially prolong the survival of tumor-bearing mice. These studies have identified doses of IL-12 that can induce impressive tumor responses without causing overt toxicity. In some tumor models, mice that had experienced complete responses after IL-12 therapy were subsequently able to reject implants of the same tumor, but not of a different tumor, suggesting that specific antitumor immunity had been established [47, 103, 104, 106]. In models of colon cancer, ovarian cancer, lung cancer, renal cell cancer and melanoma, IL-12 was found to be more effective and/or less toxic than IL-2 [8, 47, 103, 107, 108]. Moreover, a combination of IL-2 and IL-12 was more effective than either cytokine alone in models of primary and metastatic renal cell cancer [109]. IL-12 can also augment the graft-versus-tumor effect of bone marrow transplantation without promoting graft-versus-host disease [110–112].

The mechanisms underlying the antitumor activity of IL-12 are likely to be complex and have not been fully elucidated. Tumor regression in vivo is probably mediated through effects of IL-12 on the host immune system, since IL-12 has not been reported to directly inhibit the growth of malignant cells in vitro [106, 107, 113–115]. T cells appear to be required for optimal efficacy of IL-12 in several tumor models. Depletion of CD8 T cells partially inhibits, and depletion of both CD4 and CD8 T cells completely eliminates, the antitumor effect of IL-12 in some tumor models [8, 47, 104, 105]. These results suggest that CD8 and CD4 T cells can act in concert to inhibit tumor growth after IL-12 treatment. T cells do not appear to be solely responsible for the antitumor effects of IL-12, however. Indeed, NK cells have been implicated as antitumor effectors during IL-12 therapy for some tumors [102, 106, 113]. Taken together, the data suggest that no single effector cell is responsible for all of the antitumor activity of IL-12 in vivo. Depending on the experimental system employed, CD4 T cells, CD8 T cells, NK cells, macrophages or other cell types may participate in antitumor responses induced by IL-12.

How IL-12-stimulated effector cells inhibit tumor cell growth is also poorly understood. Activated T cells or NK cells could directly lyse tumor cells or could secrete cytokines that inhibit tumor cell proliferation or that stimulate other antitumor effector cells in vivo. Cytotoxic granule-mediated killing of neoplastic cells does not appear to be absolutely necessary for the antitumor activity of IL-12, because IL-12 therapy is efficacious against B16F10 melanoma in beige mice [102]. Beige mice possess relatively normal numbers of T cells and NK cells, but the granules of their cytotoxic lymphocytes and myeloid cells are defective [116–118]. Since IL-12 is known to induce IFN- secretion by T cells and NK cells, the possible contribution of IFN- to the antitumor effects of IL-12 have been investigated. Neutralization of IFN- in vivo was found to strongly inhibit the antitumor effect of IL-12 in murine models of sarcoma, melanoma and renal adenocarcinoma [47, 102, 104]. IFN- may contribute to tumor regression after IL-12 therapy by direct antiproliferative effects on tumor cells or by virtue of its immunomodulatory properties [102]. IFN- also inhibits neovascularization in vivo [119] and thus could interfere with tumor angiogenesis. Furthermore, IFN- has been shown to mediate the known anti-angiogenic effects of IL-12 [119]. However, antitumor activity of IFN- in vivo is substantially inferior to that of IL-12 [44]. IFN- production therefore may be necessary but not sufficient for the antitumor effects of IL-12.

ANTITUMOR EFFECTS OF CELLS TRANSDUCED WITH THE IL-12 GENES
Tumor cells or accessory cells genetically engineered to produce IL-12 have also been used in animal models of cancer immunotherapy. Syngeneic or allogeneic fibroblasts transfected with cDNA encoding murine IL-12 have been used to deliver bioactive IL-12 effectively to tumor-bearing mice [114, 120, 121]. Transduction of the IL-12 genes into tumor cells does not affect their proliferation in vitro but inhibits their ability to grow in immunocompetent mice [115, 122, 123]. Injection of IL-12-transduced sarcoma cells causes the rejection of contralateral nontransduced tumors placed either simultaneously or three days earlier [122]. Furthermore, mice injected with tumor cells secreting IL-12 can subsequently reject native, untransfected tumors upon rechallenge [122]. Thus, injection of IL-12-transduced tumor cells can induce specific and durable antitumor immunity in vivo. Both T cells and NK cells appear to participate in the immune response to tumors secreting IL-12 [115, 122]. A polycistronic retroviral vector containing the human p35 and p40 genes has been described that may be suitable for use in clinical trials of IL-12 gene therapy [124, 125].

	CLINICAL TRIALS OF IL-12 IN CANCER PATIENTS

Top Abstract Introduction Structure of IL-12 and... Production of IL-12 Biologic Activities of IL-12... Antitumor Effects of IL-12... Clinical Trials of IL-12... Conclusion References

 
Based on the encouraging results of IL-12 therapy in animal tumor models and confirmation of an acceptable toxicology profile in nonhuman primates [91, 92], a phase I study of recombinant human IL-12 given by bolus i.v. injection to patients with advanced solid tumors was initiated in May, 1994. This study was sponsored by Genetics Institute and was conducted at the New England Medical Center, Dana-Farber Cancer Institute, Indiana University Medical Center and the Pittsburgh Cancer Institute [126]. Cohorts of four to six patients were given a single i.v. injection of IL-12 followed two weeks later by five daily i.v. injections of IL-12 at the same dose. Patients who did not experience tumor progression or dose-limiting toxicity could receive five-day courses of IL-12 every three weeks for a maximum of six cycles. Forty patients were treated in this study, including 20 patients with renal cell cancer and 12 patients with melanoma. Doses of IL-12 as high as 500 ng/kg were given on an outpatient basis with acceptable toxicity. IL-12 therapy was associated with significant immunomodulatory effects, including production of IFN- in vivo. Common adverse effects included fever and chills, fatigue, nausea and headache. Transient anemia, leukopenia, thrombocytopenia, hyperglycemia and elevated serum transaminases were also frequently seen. Dose-limiting toxicities, including stomatitis and abnormal liver function tests, occurred in three of four patients treated at the 1000 ng/kg dose level. Objective tumor responses occurred in patients with renal cell cancer and melanoma.

Of 14 patients treated at the 500 ng/kg dose level in the phase I IL-12 trial described above, 10 patients completed 24 five-day treatment cycles without experiencing dose-limiting toxicity. In a subsequent phase II trial in advanced renal cell cancer, however, IL-12 given at a dose of 500 ng/kg i.v. daily for five days was associated with frequent and intolerable adverse effects [127]. This severe toxicity appears to have been due to a minor change in the schedule of IL-12 administration. Unlike patients in the initial phase I trial, patients in the phase II trial were not given a single i.v. dose of IL-12 two weeks before the first five-day cycle of treatment. Subsequent laboratory studies in mice and nonhuman primates have shown that administration of a single i.v. injection of IL-12 makes subsequent multiple-dose cycles tolerable; giving the same multiple-dose regimen without a preceding single dose causes severe toxicity [127]. The mechanisms responsible for this unanticipated and unusual schedule effect are under investigation. Nevertheless, the cause of the severe toxicity encountered in the phase II renal cell study has been elucidated, allowing the moratorium on IL-12 clinical trials to be discontinued. Phase I trials of IL-12 given by s.c. injection are currently in progress in patients with cancer and AIDS. It is hoped that successful completion of these trials will permit the antitumor efficacy of IL-12 to be examined in future phase II studies.

	CONCLUSION

Top Abstract Introduction Structure of IL-12 and... Production of IL-12 Biologic Activities of IL-12... Antitumor Effects of IL-12... Clinical Trials of IL-12... Conclusion References

 
IL-12 is a heterodimeric cytokine that has potent effects on innate and adaptive immunity. IL-12 induces IFN- secretion by T cells and NK cells, enhances the proliferation of activated T cells and NK cells, augments the cytolytic activity of CTL and NK cells, and supports the differentiation of Th1 helper effector cells. IL-12 stimulates in vitro antitumor activity of lymphocytes from patients with cancer and in vivo antitumor activity in many murine tumor models. Current data indicate that CD4 T cells, CD8 T cells, NK cells and IFN- may contribute to the antitumor effects of IL-12 therapy. However, further investigation is required to elucidate the precise mechanisms involved in the antitumor activity of IL-12. The results of preclinical studies suggest several potential strategies for the use of IL-12 in cancer therapy. IL-12 can induce the regression of established, bulky murine tumors, but in most preclinical models, IL-12 is more effective in animals with a smaller tumor burden. Thus, although the safety of IL-12 therapy must be confirmed in phase I trials involving patients with advanced cancer, IL-12 may prove more efficacious in the context of minimal residual disease. Administration of IL-12 as adjuvant therapy could be investigated in patients at high risk for disease recurrence after surgical resection of primary solid tumors and in high-risk patients with hematologic malignancies in complete remission after induction chemotherapy. Similarly, patients with minimal residual disease after autologous or allogeneic bone marrow or peripheral blood stem cell transplantation might be appropriate candidates for treatment in IL-12 clinical trials. Preclinical data also support the use of IL-12 together with other immune manipulations, including the administration of additional immunomodulatory cytokines, adoptive transfer of immunocompetent cells, or vaccination with tumor cells engineered to secrete cytokines or to express costimulatory molecules [100, 101, 105, 106, 109, 121, 128]. Combining IL-12 and IL-2 has produced particularly impressive results in preclinical studies [100, 109, 121, 128]. Properly designed and executed phase II and phase III clinical trials will ultimately be required to define the efficacy of cancer immunotherapy using IL-12.

	ACKNOWLEDGMENT

Top Abstract Introduction Structure of IL-12 and... Production of IL-12 Biologic Activities of IL-12... Antitumor Effects of IL-12... Clinical Trials of IL-12... Conclusion References

 
The authors are supported in part by NIH grants CA41619 (J.R.) and CA01730 (M.J.R.).

	REFERENCES

Top Abstract Introduction Structure of IL-12 and... Production of IL-12 Biologic Activities of IL-12... Antitumor Effects of IL-12... Clinical Trials of IL-12... Conclusion References

 

1. Kobayashi M, Fitz L, Ryan M et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989;170:827–845.[Abstract/Free Full Text]
2. Wolf SF, Temple PA, Kobayashi M et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple effects on T and natural killer cells. J Immunol 1991;146:3074–3081.[Abstract]
3. Stern AS, Podlaski FJ, Hulmes JD et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA 1990;87:6808–6812.[Abstract/Free Full Text]
4. Gubler U, Chua AO, Schoenhaut DA et al. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 1991;88:4143–4147.[Abstract/Free Full Text]
5. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994;84:4008–4027.[Free Full Text]
6. Wolf SF, Sieburth D, Sypek J. Interleukin 12: a key modulator of immune function. STEM CELLS 1994;12:154–168.[Abstract]
7. Hendrzak JA, Brunda MJ. Interleukin-12: biologic activity, therapeutic utility, and role in disease. Lab Invest 1995;72:619–637.[Medline]
8. Brunda MJ, Gately MK. Interleukin-12: potential role in cancer therapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology 1995. Philadelphia: J. B. Lippincott, 1995:3-18.
9. Schoenhaut DS, Chua AO, Wolitzky AG et al. Cloning and expression of murine IL-12. J Immunol 1992;148:3433–3440.[Abstract]
10. Gearing DP, Cosman D. Homology of the p40 subunit of natural killer cell stimulatory factor (NKSF) with the extracellular domain of the interleukin-6 receptor. Cell 1991;66:9–10.[Medline]
11. Merberg DM, Wolf SF, Clark SC. Sequence similarity between NKSF and the IL-6/G-CSF family. Immunol Today 1992;13:77–78.
12. Chizzonite R, Truitt T, Desai BB et al. IL-12 receptor: I. Characterization of the receptor on phytohemagglutinin-activated human lymphoblasts. J Immunol 1992;148:3117–3124.[Abstract]
13. Desai BB, Quinn PM, Wolitzky AG et al. IL-12 receptor: II. Distribution and regulation of receptor expression. J Immunol 1992;148:3125–3132.[Abstract]
14. Naume B, Gately MK, Desai BB et al. Synergistic effects of interleukin 4 and interleukin 12 on NK cell proliferation. Cytokine 1993;5:38–46.[Medline]
15. Chua AO, Chizzonite R, Desai BB et al. Expression cloning of a human IL-12 receptor component: a new member of the cytokine receptor superfamily with strong homology to gp130. J Immunol 1994;153:128–136.[Abstract]
16. Pignata C, Sanghera JS, Cossette L et al. Interleukin-12 induces tyrosine phosphorylation and activation of 44-kD mitogen-activated protein kinase in human T cells. Blood 1994;83:184–190.[Abstract/Free Full Text]
17. Pignata C, Prasad KVS, Hallek M et al. Phosphorylation of src-family lck tyrosine kinase following interleukin-12 activation of human natural killer cells. Cell Immunol 1995;165:211–216.[Medline]
18. Ihle JN, Witthuhn BA, Quelle FW et al. Signaling through the hematopoietic cytokine receptors. Annu Rev Immunol 1995;13:369–398.[Medline]
19. Ihle JN. Cytokine receptor signalling. Nature 1995;377:591–594.[Medline]
20. Bacon CM, McVicar DW, Ortaldo JR et al. Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12. J Exp Med 1995;181:399–404.[Abstract/Free Full Text]
21. Jacobson NG, Szabo SJ, Weber-Nordt RM et al. Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activation of transcription (Stat) 3 and Stat4. J Exp Med 1995;181:1755–1762.[Abstract/Free Full Text]
22. Szabo SJ, Jacobson NG, Dighe AS et al. Developmental commitment to the Th2 lineage by extinction of IL-12 signaling. Immunity 1995;2:665–675.[Medline]
23. Pignata C, Prasad KVS, Robertson MJ et al. FcRIIIA-mediated signaling involves src-family lck in human natural killer cells. J Immunol 1993;151:6794–6800.[Abstract]
24. D’Andrea A, Rengaraju M, Valiante NM et al. Production of natural killer cell stimulatory factor (interleukin-12) by peripheral blood mononuclear cells. J Exp Med 1992;176:1387–1398.[Abstract/Free Full Text]
25. Kubin M, Chow JM, Trinchieri G. Differential regulation of interleukin-12 (IL-12), tumor necrosis factor , and IL-1ß production in human myeloid leukemia cell lines and peripheral blood mononuclear cells. Blood 1994;83:1847–1855.[Abstract/Free Full Text]
26. Mattner F, Fischer S, Guckes S et al. The interleukin-12 subunit p40 specifically inhibits effects of the interleukin-12 heterodimer. Eur J Immunol 1993;23:2202–2208.[Medline]
27. Ling P, Gately MK, Gubler U et al. Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol 1994;154:116–127.[Abstract]
28. Aragane Y, Riemann H, Bhardwaj RS et al. IL-12 is expressed and released by human keratinocytes and epidermoid carcinoma cell lines. J Immunol 1994;153:5366–5372.[Abstract]
29. Macatonia SE, Hosken NA, Litton M et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4⁺ T cells. J Immunol 1995;154:5071–5079.[Abstract]
30. Cassatella MA, Meda L, Gasperini S et al. Interleukin-12 production by human polymorphonuclear leukocytes. Eur J Immunol 1995;25:1–5.[Medline]
31. Muller G, Saloga J, Germann T et al. Identification and induction of human keratinocyte-derived IL-12. J Clin Invest 1994;94:1799–1805.
32. Smith TJ, Ducharme LA, Weis JH. Preferential expression of interleukin-12 or interleukin-4 by murine bone marrow mast cells derived in mast cell growth factor or interleukin-3. Eur J Immunol 1994;24:822–826.[Medline]
33. D’Andrea A, Aste-Amezaga M, Valiante NM et al. Interleukin 10 (IL-10) inhibits human lymphocyte interferon -production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993;178:1041–1048.[Abstract/Free Full Text]
34. Chan SH, Perussia B, Gupta JW et al. Induction of interferon production by natural killer cell stimulatory factor: characterization of responder cells and synergy with other inducers. J Exp Med 1991;173:869–879.[Abstract/Free Full Text]
35. Chan SH, Kobayashi M, Santoli D et al. Mechanisms of IFN- induction by natural killer cell stimulatory factor (NKSF/IL-12): role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. J Immunol 1992;148:92–98.[Abstract]
36. Carson WE, Ross ME, Baiocchi RA et al. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon- by natural killer cells in vitro. J Clin Invest 1995;96:2578–2582.
37. Gazzinelli RT, Hieny S, Wynn TA et al. Interleukin 12 is required for the T-lymphocyte-independent induction of interferon by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc Natl Acad Sci USA 1993;90:6115–6119.[Abstract/Free Full Text]
38. Tripp CS, Wolf SF, Unanue ER. Interleukin 12 and tumor necrosis factor are costimulators of interferon production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci USA 1993;90:3725–3729.[Abstract/Free Full Text]
39. Wu C-Y, Demeure C, Kiniwa M et al. IL-12 induces the production of IFN- by human neonatal CD4 T cells. J Immunol 1993;151:1938–1949.[Abstract]
40. Kubin M, Kamoun M, Trinchieri G. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J Exp Med 1994;180:211–222.[Abstract/Free Full Text]
41. Murphy EE, Terres G, Macatonia SE et al. B7 and interleukin 12 cooperate for proliferation and interferon production by mouse T helper clones that are unresponsive to B7 costimulation. J Exp Med 1994;180:223–231.[Abstract/Free Full Text]
42. Gollob JA, Li J, Reinherz EL et al. CD2 regulates responsiveness of activated T cells to interleukin 12. J Exp Med 1995;182:721–731.[Abstract/Free Full Text]
43. Gately MK, Warrier RR, Honasoge S et al. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN- in vivo. Int Immunol 1994;6:157–167.[Abstract/Free Full Text]
44. Brunda MJ, Luistro L, Hendrzak JA et al. Role of interferon- in mediating the antitumor efficacy of interleukin-12. J Immunother 1995;17:71–77.
45. Heinzel FP, Schoenhaut DS, Rerko RM et al. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 1993;177:1505–1509.[Abstract/Free Full Text]
46. Orange JS, Wang B, Terhorst C et al. Requirement for natural killer cell-produced interferon in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration. J Exp Med 1995;182:1045–1056.[Abstract/Free Full Text]
47. Nastala CL, Edington HD, McKinney TG et al. Recombinant IL-12 administration induces tumor regression in association with IFN- production. J Immunol 1994;153:1697–1706.[Abstract]
48. Locksley RM. Interleukin 12 in host defense against microbial pathogens. Proc Natl Acad Sci USA 1993;90:5879–5880.[Free Full Text]
49. Scott P. IL-12: initiation cytokine for cell-mediated immunity. Science 1993;260:496–497.[Free Full Text]
50. Romagnani S. Induction of T_H1 and T_H2 responses: a key role for the "natural" immune response? Immunol Today 1992;13:379–381.[Medline]
51. Naume B, Gately M, Espevik T. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56⁺ NK cells. J Immunol 1992;148:2429–2436.[Abstract]
52. Naume B, Johnsen A-C, Espevik T et al. Gene expression and secretion of cytokines and cytokine receptors from highly purified CD56⁺ natural killer cells stimulated with interleukin-2, interleukin-7, and interleukin 12. Eur J Immunol 1993;23:1831–1838.[Medline]
53. Aste-Amezaga M, D’Andrea A, Kubin M et al. Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells. Cell Immunol 1994;156:480–492.[Medline]
54. Gately MK, Desai BB, Wolitzky AG et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 1991;147:874–882.[Abstract]
55. Bertagnolli MM, Lin B-Y, Young D et al. IL-12 augments antigen-dependent proliferation of activated T lymphocytes. J Immunol 1992;149:3778–3783.[Abstract]
56. Perussia B, Chan SH, D’Andrea A et al. Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-ß⁺, TCR-⁺ T lymphocytes, and NK cells. J Immunol 1992;149:3495–3502.[Abstract]
57. Robertson MJ, Soiffer RJ, Wolf SF et al. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells is differentially regulated by NKSF. J Exp Med 1992;175:779–788.[Abstract/Free Full Text]
58. Robertson MJ, Manley TJ, Donahue C et al. Costimulatory signals are required for optimal proliferation of human natural killer cells. J Immunol 1993;150:1705–1714.[Abstract]
59. Rabinowich H, Herberman RB, Whiteside TL. Differential effects of IL 12 and IL 2 on expression and function of cellular adhesion molecules on purified human natural killer cells. Cell Immunol 1993;152:481–498.[Medline]
60. Sitkovsky MV, Henkart PA, eds. Cytotoxic Cells: Recognition, Effector Function, Generation, and Methods. Boston, MA: Birkhauser, 1993.
61. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990;76:2421–2438.[Free Full Text]
62. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989;47:187–377.[Medline]
63. Trinchieri G, Valiante N. Receptors for the Fc fragment of IgG on natural killer cells. Nat Immun 1993;12:218–234.[Medline]
64. Bezouska K, Yuen C-T, O’Brien J et al. Oligosaccharide ligands for NKR-P1 protein activate NK cells and cytotoxicity. Nature 1994;372:150–157.[Medline]
65. Anderson SK, Gallinger S, Roder J et al. A cyclophilin-related protein involved in the function of natural killer cells. Proc Natl Acad Sci USA 1993;90:542–546.[Abstract/Free Full Text]
66. Harris DT, Jaso-Friedmann L, Devlin RB et al. Identification of an evolutionarily conserved, function-associated molecule on human natural killer cells. Proc Natl Acad Sci USA 1991;88:3009–3013.[Abstract/Free Full Text]
67. Valiante NM, Trinchieri G. Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes. J Exp Med 1993;178:1397–1406.[Abstract/Free Full Text]
68. Gumperz JE, Parham P. The enigma of the natural killer cell. Nature 1995;378:245–248.[Medline]
69. Trinchieri G. Recognition of major histocompatibility complex class I antigens by natural killer cells. J Exp Med 1994;180:417–421.[Free Full Text]
70. Gately MK, Wolitzky AG, Quinn PM et al. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol 1992;143:127–142.[Medline]
71. Chouaib S, Chehimi J, Bani L et al. Interleukin 12 induces the differentiation of major histocompatibility complex class I-primed cytotoxic T lymphocyte precursors into allospecific cytotoxic effectors. Proc Natl Acad Sci USA 1994;91:12659–12663.[Abstract/Free Full Text]
72. Mehrotra PT, Wu D, Crim JA et al. Effects of IL-12 on the generation of cytotoxic activity in human CD8⁺ T lymphocytes. J Immunol 1993;151:2444–2452.[Abstract]
73. Chehimi J, Valiante NM, D’Andrea A et al. Enhancing effect of natural killer cell stimulatory factor (NKSF/interleukin-12) on cell-mediated cytotoxicity against tumor-derived and virus-infected cells. Eur J Immunol 1993;23:1826–1830.[Medline]
74. Lieberman MD, Sigal RK, Williams NN II et al. Natural killer cell stimulatory factor (NKSF) augments natural killer cell and antibody-dependent tumoricidal responses against colon carcinoma cell lines. J Surg Res 1991;50:410–415.[Medline]
75. Salcedo TW, Azzoni L, Wolf SF et al. Modulation of perforin and granzyme messenger RNA expression in human natural killer cells. J Immunol 1993;151:2511–2520.[Abstract]
76. Cesano A, Visonneau S, Clark SC et al. Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12. J Immunol 1993;151:2943–2957.[Abstract]
77. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994;76:241–251.[Medline]
78. Trinchieri G. Interleukin-12 and its role in the generation of T_H1 cells. Immunol Today 1993;14:335–338.[Medline]
79. Hsieh C-S, Macatonia SE, Tripp CS et al. Development of T_H1 CD4⁺ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993;260:547–549.[Abstract/Free Full Text]
80. Scharton TM, Scott P. Natural killer cells are a source of interferon that drives differentiation of CD4⁺ T cell subsets and induces early resistance to Leishmania major in mice. J Exp Med 1993;178:567–577.[Abstract/Free Full Text]
81. Seder RA, Gazzinelli R, Sher A et al. Interleukin 12 acts directly on CD4⁺ T cells to enhance priming for interferon production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA 1993;90:10188–10192.[Abstract/Free Full Text]
82. Manetti R, Parronchi P, Grazia M et al. Natural killer cell stimulatory factor (interleukin-12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993;177:1199–1204.[Abstract/Free Full Text]
83. Jacobsen SEW, Veiby OP, Smeland EB. Cytotoxic lymphocyte maturation factor (interleukin 12) is a synergistic growth factor for hematopoietic stem cells. J Exp Med 1993;178:413–418.[Abstract/Free Full Text]
84. Hirayama F, Katayama N, Neben S et al. Synergistic interaction between interleukin-12 and Steel factor in support of the proliferation of murine lymphohematopoietic progenitors in culture. Blood 1993;83:92–98.[Abstract/Free Full Text]
85. Bellone G, Trinchieri G. Dual stimulatory and inhibitory effect of NK cell stimulatory factor/IL-12 on human hematopoiesis. J Immunol 1994;153:930–937.[Abstract]
86. Hirao A, Takaue Y, Kawano Y et al. Synergism of interleukin 12, interleukin 3, and serum factor on primitive human hematopoietic progenitor cells. STEM CELLS 1995;13:47–53.[Abstract]
87. Dybedal I, Larsen S, Jacobsen SEW. IL-12 directly enhances in vitro murine erythropoiesis in combination with IL-4 and stem cell factor. J Immunol 1995;154:4950–4955.[Abstract]
88. Tare NS, Bowen S, Warrier RR et al. Administration of recombinant interleukin-12 to mice suppresses hematopoiesis in the bone marrow but enhances hematopoiesis in the spleen. J Interferon Cytokine Res 1995;15:377–383.[Medline]
89. Jackson JD, Yan Y, Brunda MJ et al. Interleukin-12 enhances peripheral hematopoiesis in vivo. Blood 1995;85:2371–2376.[Abstract/Free Full Text]
90. Eng VM, Car BD, Schnyder B et al. The stimulatory effects of interleukin (IL)-12 on hematopoiesis are antagonized by IL-12-induced interferon in vivo. J Exp Med 1995;181:1893–1898.[Abstract/Free Full Text]
91. Bree AG, Schlerman FJ, Kaviani MD et al. Multiple effects on peripheral hematology following administration of recombinant human interleukin 12 to nonhuman primates. Biochem Biophys Res Commun 1994;204:1150–1157.[Medline]
92. Sarmiento UM, Riley JH, Knaack PA et al. Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri). Lab Invest 1994;71:862–873.[Medline]
93. Soiffer RJ, Robertson MJ, Murray C et al. Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood 1993;82:2790–2796.[Abstract/Free Full Text]
94. Rossi AR, Pericle F, Rashleigh S et al. Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood 1994;83:1323–1328.[Abstract/Free Full Text]
95. Rook AH, Kubin M, Cassin M et al. IL-12 reverses cytokine and immune abnormalities in Sézary syndrome. J Immunol 1995;154:1491–1498.[Abstract]
96. Zeh HJ III, Hurd S, Storkus WJ et al. Interleukin 12 promotes the proliferation and cytolytic activity of immune effectors: implications for the immunotherapy of cancer. J Immunotherapy 1993;14:155–161.
97. Andrews JVR, Schoof DK, Bertagnolli MM et al. Immunomodulatory effects of interleukin 12 on human tumorinfiltrating lymphocytes. J Immunotherapy 1993;14:1–10.
98. Bigda J, Mysliwska J, Dziadziuszko R et al. Interleukin 12 augments natural killer cell mediated cytotoxicity in hairy cell leukemia. Leuk Lymphoma 1993;10:121–125.[Medline]
99. Caligiuri MA, Murray C, Robertson MJ et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest 1993;91:123–132.
100. Hill LL, Perussia B, McCue PA et al. Effect of human natural killer cells on the metastatic growth of human melanoma xenografts in mice with severe combined immunodeficiency. Cancer Res 1994;54:763–770.[Abstract/Free Full Text]
101. Cesano A, Visonneau S, Cioe L et al. Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach. J Clin Invest 1994;94:1076–1084.
102. Brunda MJ, Luistro L, Warrier RR et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993;178:1223–1230.[Abstract/Free Full Text]
103. Mu J, Zou J-P, Yamamoto N et al. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res 1995;55:4404–4408.[Abstract/Free Full Text]
104. Zou J-P, Yamamoto N, Fujii T et al. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN- production by anti-tumor T cells. Int Immunol 1995;7:1135–1145.[Abstract/Free Full Text]
105. Noguchi Y, Richards EC, Chen Y-T et al. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA 1995;92:2219–2223.[Abstract/Free Full Text]
106. Coughlin CM, Wysocka M, Kurzawa HL et al. B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res 1995;55:4980–4987.[Abstract/Free Full Text]
107. Brunda MJ, Luistro L, Warrier R et al. Antitumor activity of interleukin-12 in murine tumor models. Proc Am Soc Cancer Res 1993;34:464a.
108. Stern LL, Tarby CM, Tamborini B et al. Preclinical development of IL-12 as an anticancer drug: comparison to IL-2. Proc Am Soc Cancer Res 1994;35:520a.
109. Wigginton JM, Komschlies KL, Back TC et al. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst 1996;88:38–43.[Abstract/Free Full Text]
110. Sykes M, Pearson DA, Szot GL et al. Exogenous IL-12 administration separates graft-versus-host disease and graft-versus-leukemia effects. In: Champlin RE, Horowitz MM, Kersey JH et al., eds. American Society for Blood and Marrow Transplantation. Keystone, CO: Medical College of Wisconsin, 1995:32a.
111. Sykes M, Szot GL, Nguyen PL et al. Interleukin-12 inhibits murine graft-versus-host disease. Blood 1995;86:2429–2438.[Abstract/Free Full Text]
112. Verbik DJ, Stinson WW, Brunda MJ et al. Therapeutic effects of in vivo administration of interleukin-12 against residual lymphoma. Proc Am Assoc Cancer Res 1995;36:480a.
113. O’Toole M, Wolf SF, O’Brien C et al. Effect of in vivo IL-12 administration on murine tumor cell growth. J Immunol 1993;150:294a.
114. Tahara H, Zeh HJ III, Storkus WJ et al. Fibroblast genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994;54:182–189.[Abstract/Free Full Text]
115. Martinotti A, Stoppacciaro A, Vagliani M et al. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur J Immunol 1995;25:137–146.[Medline]
116. Clark EA, Roths JB, Murphy ED et al. The beige (bg) gene influences the development of autoimmune disease in SB/Le male mice. In: Herberman RB, ed. NK Cells and Other Natural Effector Cells. New York: Academic Press, 1982:301-306.
117. Halle-Pannenko O, Bruley-Rosset M. Decreased graft-versus-host reaction and T cell cytolytic potential of beige mice. Transplantation 1985;39:85–87.[Medline]
118. Biron CA, Pedersen KF, Welsh RM. Aberrant T cells in beige mutant mice. J Immunol 1987;138:2050–2056.[Abstract]
119. Voest EE, Kenyon BM, O’Reilly MS et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995;87:581–586.[Abstract/Free Full Text]
120. Zitvogel L, Tahara H, Robbins PD et al. Cancer immunotherapy of established tumors with IL-12: effective delivery by genetically engineered fibroblasts. J Immunol 1995;155:1393–1403.[Abstract]
121. Pappo I, Tahara H, Robbins PD et al. Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy. J Surg Res 1995;58:218–226.[Medline]
122. Tahara H, Zitvogel L, Storkus WJ et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995;154:6466–6474.[Abstract]
123. Meko JB, Yim JH, Tsung K et al. High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. Cancer Res 1995;55:4765–4770.[Abstract/Free Full Text]
124. Zitvogel L, Tahara H, Mueller G et al. Construction and characterization of retroviral vectors expressing biologically active human IL-12. Human Gene Therapy 1994;5:1493–1506.[Medline]
125. Tahara H, Lotze MT. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Therapy 1995;2:96–106.[Medline]
126. Atkins MB, Robertson M, Gordon MS et al. Phase I evaluation of intravenous recombinant human interleukin 12 (rhIL-12) in patients with advanced malignancies. Proc Am Soc Clin Oncol 1996 (in press).
127. Cohen J. IL-12 deaths: explanation and a puzzle. Science 1995;270:908.
128. Vagliani M, Rodolfo M, Cavallo F et al. Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. Cancer Res 1996;56:467–470.[Abstract/Free Full Text]

This article has been cited by other articles:

				S. M. Meeran, S. Katiyar, C. A. Elmets, and S. K. Katiyar Interleukin-12 Deficiency Is Permissive for Angiogenesis in UV Radiation-Induced Skin Tumors Cancer Res., April 15, 2007; 67(8): 3785 - 3793. [Abstract] [Full Text] [PDF]

W. R. Coward, A. Marei, A. Yang, M. M. Vasa-Nicotera, and S. C. Chow Statin-Induced Proinflammatory Response in Mitogen-Activated Peripheral